Newsroom

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders, today issued the following statement supporting the newly signed White House Executive Order aimed at accelerating research, development, and responsible access to innovative treatments for serious mental illness, including emerging psychedelic medi...

PHOENIX--(BUSINESS WIRE)--At this year’s American Society of Regional Anesthesia and Pain Medicine (ASRA) annual meeting, researchers at Hospital for Special Surgery (HSS) presented two studies focused on glucagon-like peptide-1 (GLP-1) agonist usage in patients undergoing surgery. GLP-1 agonists are a class of medications commonly prescribed to treat type 2 diabetes and obesity, and their therapeutic potential is extending to a range of conditions including cardiovascular and neurodegenerative...

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Researchers from Inocras, a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to advance precision health, and the Broad Institute of MIT and Harvard will jointly present new insights from a collaborative initiative to analyze large-scale whole genome data during the AACR Annual Meeting 2026 in San Diego. The collaboration delivers one of the largest cancer whole-genome analyses from over 8,000 cancer wh...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could h...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Green Circle Decarbonize Technology Ltd. (NYSE American: GCDT) resulting from allegations that Green Circle may have issued materially misleading business information to the investing public. So what: If you purchased Green Circle securities you may be entitled to compensation without payment of any out of pocket fees or costs...

DALLAS--(BUSINESS WIRE)--This week, the nationally recognized law firm Baron & Budd announced the finalization of a $774 million nationwide settlement agreement with retail pharmacy giant Albertsons Companies, Inc. Albertsons has agreed to the payout which will be distributed to states, counties, municipalities, and Native American tribes to resolve allegations concerning the company’s role in the opioid epidemic. Baron & Budd’s President and Managing Shareholder, Russell Budd, played a...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Enphase Energy, Inc. (NASDAQ: ENPH) between April 22, 2025 and October 28, 2025, inclusive (the “Class Period”). Enphase is a energy technology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Enphase En...

PHOENIX--(BUSINESS WIRE)--At this year’s American Society of Regional Anesthesia and Acute Pain Medicine (ASRA) annual meeting, investigators at Hospital for Special Surgery (HSS) presented significant studies leveraging artificial intelligence (AI) to provide insights into long-term pain risk after surgery and what patients want to know about anesthesia. These insights may ultimately help guide anesthesiologists’ consultations with patients scheduled for surgery. What follows are highlights fr...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from a preclinical study of ZL-1503, demonstrating that the company’s internally developed IL-13/IL-31Rα bispecific antibody may lead to sustained suppression of intense pruritus (itch) and inflammation caused by atopic diseases. The findings, featured in a poster presentation at the IMMUNOLOGY2026 conference in Boston, MA, reinforce the potential of ZL-1503 to be a first-in-class t...

PARSONS, Kan.--(BUSINESS WIRE)--Deep Fission, Inc. (“Deep Fission” or the “Company”), will host a community engagement webinar on Tuesday, April 21, at 7 p.m. CDT, inviting the public to learn more about the company’s advanced nuclear energy project in Parsons, Kansas. The webinar will feature Deep Fission Chief Operating Officer Mike Brasel, who will provide an overview of the company’s technology, project plans, and ongoing community efforts. Attendees will have the opportunity to submit ques...